卷积变异自动编码器和视觉转换器混合方法,用于增强早期阿尔茨海默病检测
Harshani Fonseka1, Soheil Varastehpour1, Masoud Shakiba1
1Unitec Institute of Technology, School of Computing, Electrical and Applied Technology, Auckland, New Zealand.
Journal of medical imaging (Bellingham, Wash.)
|May 26, 2025
概括
结合CVAE和ViT的新混合深度学习模型使用MRI扫描准确检测早期阿尔茨海默病 (AD). 这种方法显著提高了诊断准确度,为阿兹海默症患者早期干预提供了希望.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阿尔茨海默病 (AD) 的患病率正在上升,需要改进早期检测方法.
- 目前针对阿尔茨海默病的治疗方法在早期开始时最有效.
- 早期诊断对于管理阿尔茨海默病的进展至关重要.
研究的目的:
- 开发和评估一种新的混合深度学习模型,用于自动诊断阿尔茨海默病.
- 通过医学图像分析提高AD检测的精度和速度.
- 利用深度学习来识别认知障碍的早期指标.
主要方法:
- 提出了一种混合模型,将卷积变化自动编码器 (CVAE) 与视觉变压器 (ViT) 集成在一起.
- CVAE用于从MRI扫描中提取特征和降低噪音.
- 具有多头注意力的ViT分析了精细的MRI数据以进行模式识别.
主要成果:
- 该CVAE-ViT模型在来自ADNI和SCAN数据库的14000个结构MRI扫描上进行了训练和验证.
- 达到93.3%的测试准确度,超过了三个基准方法.
- 与之前的阿尔茨海默氏症分类技术相比,显著改善.
结论:
- 混合CVAE-ViT方法显示了检测细微的结构异常的潜力,这表明AD.
- 使用CVAE无监督的特征提取增强了用于认知障碍分期的变压器模型.
- 这种方法可以显著改善早期阿尔茨海默病指标的识别.
相关概念视频
Alzheimer's Disease: Treatment
266
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
266
Alzheimer's Disease: Overview
689
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
689


